Jami Rubin

Jami Rubin News

  • Goldman Warns of Teva Selloff as Copaxone Threat Looms

    Teva Pharmaceutical Industries Ltd.’s best quarterly rally since 2003 prompted analysts at Goldman Sachs Group Inc. to abandon their sell rating on the stock earlier this year. Now they’re telling investors to buy insurance against a potential plunge in the shares.

  • Pfizer Needs to Rebuild After Lipitor

    Pfizer Inc.’s long dependence on the cholesterol pill Lipitor to produce almost one-fifth of the company’s revenue begins eroding today when the drug’s patent protection ends in the U.S.

  • Pfizer Rises After Goldman Raises Potential for Full Breakup

    Pfizer Inc., the world’s largest drugmaker, rose to its highest price in more than four years after Goldman Sachs Group Inc. analysts said the company may go beyond the divestiture plans it has already announced.

  • AbbVie Beats Estimates as Sales of Humira Continues Climb

    AbbVie Inc., the drugmaker carved out of Abbott Laboratories at the start of the year, reported profit that beat analysts’ estimates and raised its 2013 forecast after sales of top medicine Humira gained on price increases and new indications.

  • At $84,000 Gilead Hepatitis C Drug Sets Off Payer Revolt

    As Gilead Sciences Inc. touted its $1,000-a-pill hepatitis C cure to investors in a hotel ballroom in San Francisco, a group of about 20 protesters milled outside. “Gilead=Greed,” one sign read.

  • Pfizer’s Possible Unit Shuffle Triggers Breakup Concern

    Pfizer Inc.’s four business units may be combined into two, a top company official said, triggering speculation by analysts that the world’s biggest drugmaker is preparing to split in half.

  • Abbott Spinoff May Fetch $54 Billion as Humira Tempts Rivals

    The breakup of Abbott Laboratories into two companies will create a prescription-medicine spinoff that may become a $54 billion target for drugmakers looking to rejuvenate their flagging portfolios.

  • J&J AIDS Pill Signals $9 Billion in Sales to Ease Recall Woes

    Johnson & Johnson , the drugmaker that won approval last week for the first new AIDS medicine since 2008, plans to introduce four drugs this year that may combine for annual sales of $9 billion, helping to offset product recalls and declining profit for medical devices.

  • Pfizer’s Two New Top Pills Selling Slower Than Expected

    Pfizer Inc.’s touted two new drugs aren’t selling as fast as the company anticipated, a top executive said today, though the drugmaker expects the pills should still become blockbusters.

  • AbbVie Profit Beats Estimates as Sales of Humira Increase

    AbbVie Inc., the drugmaker that split from Abbott Laboratories in January, reported third- quarter earnings that beat analysts’ estimates as sales of its top drug Humira increased. The company raised the bottom end of its full-year forecast.

Sponsored Links
Curation software by Lingospot